• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Safety of esthetic procedures in rheumatic patients: single-center survey of patients.风湿患者美容治疗的安全性:单中心患者调查。
Rheumatol Int. 2024 Feb;44(2):357-362. doi: 10.1007/s00296-023-05481-5. Epub 2023 Oct 17.
2
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.COVID-19 相关住院风险因素在自身免疫性炎症性风湿病患者中的分析。
Ann Rheum Dis. 2020 Nov;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984. Epub 2020 Aug 7.
3
Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties.抗风湿治疗与人工关节感染:494 例择期髋关节和膝关节置换术的观察性研究。
BMC Musculoskelet Disord. 2020 Jun 29;21(1):410. doi: 10.1186/s12891-020-03459-z.
4
Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.自身免疫性风湿病患者接受生物 DMARDs 治疗后的结核以外感染发生率:来自印度的实时临床经验。
Rheumatol Int. 2019 Mar;39(3):497-507. doi: 10.1007/s00296-019-04245-4. Epub 2019 Jan 25.
5
Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.沙特风湿性疾病儿童的生物制剂治疗:适应证与安全性
Int J Rheum Dis. 2016 Jun;19(6):600-5. doi: 10.1111/1756-185X.12365. Epub 2014 Apr 15.
6
Antirheumatic drugs in older adults and polypharmacy issues.老年人抗风湿药物与多重用药问题。
Z Gerontol Geriatr. 2022 Oct;55(6):507-512. doi: 10.1007/s00391-021-01907-6. Epub 2021 Jun 10.
7
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征:来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
8
Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects.抗肿瘤坏死因子治疗慢性风湿性疾病的安全性:与副作用相关的治疗中断情况。
J Clin Pharm Ther. 2016 Jun;41(3):306-9. doi: 10.1111/jcpt.12393.
9
Perceptions of Pregnancy and Lactation from the Pregnancy and Lactation Autoimmune Network Registry.来自妊娠和哺乳期自身免疫网络注册研究的妊娠和哺乳认知。
J Rheumatol. 2020 Jan;47(1):149-154. doi: 10.3899/jrheum.181067. Epub 2019 Apr 1.
10
Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.类风湿关节炎成年患者使用疾病修正抗风湿药物与新发心血管事件风险:巢式病例对照研究。
Clin Rheumatol. 2024 Jan;43(1):103-116. doi: 10.1007/s10067-023-06709-2. Epub 2023 Aug 4.

引用本文的文献

1
Granulomatous Reaction to Lip Filler in a Patient with Ankylosing Spondylitis: A Case Report.强直性脊柱炎患者唇部填充剂的肉芽肿反应:一例报告
Cureus. 2024 Oct 7;16(10):e71032. doi: 10.7759/cureus.71032. eCollection 2024 Oct.

本文引用的文献

1
Hyaluronic Acid Filler Injection for Localized Scleroderma - Case Report and Review of Literature on Filler Injections for Localized Scleroderma.透明质酸填充剂注射治疗局限性硬皮病——病例报告及局限性硬皮病填充剂注射文献综述
Clin Cosmet Investig Dermatol. 2022 Aug 11;15:1627-1637. doi: 10.2147/CCID.S356641. eCollection 2022.
2
2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.2022 年美国风湿病学会/美国髋膝关节外科医师学会择期全髋关节或全膝关节置换术患者抗风湿药物围手术期管理指南。
Arthritis Care Res (Hoboken). 2022 Sep;74(9):1399-1408. doi: 10.1002/acr.24893. Epub 2022 Jun 19.
3
Tattooing in Psoriasis: A Questionnaire-Based Analysis of 150 Patients.银屑病患者纹身情况:基于问卷调查的150例患者分析
Clin Cosmet Investig Dermatol. 2022 Apr 6;15:587-593. doi: 10.2147/CCID.S348165. eCollection 2022.
4
The Immunogenicity of Hyaluronic Fillers and Its Consequences.透明质酸填充剂的免疫原性及其后果。
Clin Cosmet Investig Dermatol. 2021 Jul 16;14:921-934. doi: 10.2147/CCID.S316352. eCollection 2021.
5
Breast implant illness: a topic in review.乳房植入物疾病:综述主题
Gland Surg. 2021 Jan;10(1):430-443. doi: 10.21037/gs-20-231.
6
A Systematic Review Supporting the American Society for Dermatologic Surgery Guidelines on the Prevention and Treatment of Adverse Events of Injectable Fillers.支持美国皮肤外科学会关于注射填充剂不良事件的预防和治疗指南的系统评价。
Dermatol Surg. 2021 Feb 1;47(2):227-234. doi: 10.1097/DSS.0000000000002911.
7
Dermal Filler Injections in Patients With Autoimmune and Inflammatory Rheumatic Diseases-The Patients' Perspective.自身免疫性和炎性风湿性疾病患者接受真皮填充剂注射的患者视角
Dermatol Surg. 2022 Jan 1;48(1):82-86. doi: 10.1097/DSS.0000000000002888.
8
Increased risk of late-onset, immune-mediated, adverse reactions related to dermal fillers in patients bearing HLA-B*08 and DRB1*03 haplotypes.携带 HLA-B*08 和 DRB1*03 单倍型的患者中,真皮填充剂相关迟发性、免疫介导的不良反应风险增加。
Dermatol Ther. 2021 Jan;34(1):e14644. doi: 10.1111/dth.14644. Epub 2020 Dec 19.
9
Cosmetic treatment in patients with autoimmune connective tissue diseases: Best practices for patients with lupus erythematosus.自身免疫性结缔组织病患者的美容治疗:红斑狼疮患者的最佳实践。
J Am Acad Dermatol. 2020 Aug;83(2):343-363. doi: 10.1016/j.jaad.2020.03.123. Epub 2020 Apr 28.
10
Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis.硅树脂乳房植入物与自身免疫/风湿性疾病风险:真实世界分析。
Int J Epidemiol. 2018 Dec 1;47(6):1846-1854. doi: 10.1093/ije/dyy217.

风湿患者美容治疗的安全性:单中心患者调查。

Safety of esthetic procedures in rheumatic patients: single-center survey of patients.

机构信息

Biologic Therapy Center, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.

Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637, Warsaw, Poland.

出版信息

Rheumatol Int. 2024 Feb;44(2):357-362. doi: 10.1007/s00296-023-05481-5. Epub 2023 Oct 17.

DOI:10.1007/s00296-023-05481-5
PMID:37847387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10796409/
Abstract

The popularity of esthetic medicine is growing every year, also among patients with autoimmune inflammatory rheumatic diseases (AIRD). The objective of this study was to evaluate the safety of esthetic medicine (AM) procedures in patients with AIRD. A semi-structured, anonymous questionnaire regarding rheumatic and concomitant diseases and AM procedures was distributed among adult patients hospitalized in the rheumatology department or attending outpatient clinic in the National Institute of Geriatrics, Rheumatology, and Rehabilitation, Warsaw. The main outcome was the occurrence of an adverse event. A number of 512 patients took part in the survey and 15 were excluded (AM procedure preceded the diagnosis of AIRD). The study group consisted of 497 patients, of whom 47 had undergone AM procedures. The procedures performed included: tattooing (22 patients), piercing (16 patients), hyaluronic acid (7 patients), botulinum toxin (5 patients) injections, laser procedures (6 patients), plastic surgery (4 patients), mesotherapy (3 patients) and others. The vast majority of patients had these performed during remission or low disease activity. 70.2% of patients received treatment with disease-modifying antirheumatic drugs (DMARDs) during the AM procedure, with TNF-alfa inhibitors being the most common (63.6%). Adverse events occurred in 15% of patients. All were mild and transient site reactions. Most patients would like to repeat the AM procedure in the future. The use of esthetic medicine procedures in patients with AIRD, including those treated with biologic DMARDs, was associated with a risk of mild site reactions. Most of the patients expressed satisfaction with the results of the AM procedure.

摘要

美容医学的受欢迎程度每年都在增长,在自身免疫性炎症性风湿病(AIRD)患者中也是如此。本研究的目的是评估美容医学(AM)程序在 AIRD 患者中的安全性。一项关于风湿病和合并症以及 AM 程序的半结构化、匿名问卷分发给了在华沙国家老年病学、风湿病学和康复研究所住院的成年患者或在门诊就诊的患者。主要结果是不良事件的发生。共有 512 名患者参加了调查,其中 15 名被排除(AM 程序先于 AIRD 诊断)。研究组包括 497 名患者,其中 47 名患者接受了 AM 程序。进行的程序包括:纹身(22 名患者)、穿孔(16 名患者)、透明质酸(7 名患者)、肉毒杆菌毒素(5 名患者)注射、激光治疗(6 名患者)、整形手术(4 名患者)、中胚层疗法(3 名患者)和其他。绝大多数患者在缓解期或疾病活动度低时进行这些治疗。70.2%的患者在 AM 手术期间接受了疾病修饰抗风湿药物(DMARDs)治疗,其中最常见的是 TNF-alfa 抑制剂(63.6%)。15%的患者出现了不良事件。所有这些都是轻微的和短暂的部位反应。大多数患者希望将来再次接受 AM 手术。在 AIRD 患者中使用美容医学程序,包括使用生物 DMARDs 的患者,与轻度部位反应的风险相关。大多数患者对 AM 程序的结果表示满意。